Survival function analysis of mortality for Viral load status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Multivariate Cox proportional hazard analysis ratio of patient factors associated with treatment outcomes in HIV care, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Clinic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of treatment Interruption for Viral load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of viral suppression for BMI status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Schematic presentation of sampling of population for analysis. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival curve of ART Treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by clinical characteristics <i>among participants in HIV care Facilities in</i> Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by clinical characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Cumulative treatment outcomes prevalence rates for patients in ART treatment from year 2020 to 2022 for study participant in Bauchi State. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis for LTFU according to Viral Load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Demographic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Annual incidence rate per 100 person-years trend for ART treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Table 5_PABPN1 as a pan-cancer biomarker: prognostic significance and association with tumor immune microenvironment.xlsx by Hong-Xing Li (316258)

“…After down expression of PABPN1, mRNA expression levels of MRPS15 and GPx (Glutathione peroxidase) decreased significantly in T24, 5637 HLF and MCF-7 cells.…”

Image 8_PABPN1 as a pan-cancer biomarker: prognostic significance and association with tumor immune microenvironment.tif by Hong-Xing Li (316258)

“…After down expression of PABPN1, mRNA expression levels of MRPS15 and GPx (Glutathione peroxidase) decreased significantly in T24, 5637 HLF and MCF-7 cells.…”

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

Table 2_PABPN1 as a pan-cancer biomarker: prognostic significance and association with tumor immune microenvironment.xlsx by Hong-Xing Li (316258)

“…After down expression of PABPN1, mRNA expression levels of MRPS15 and GPx (Glutathione peroxidase) decreased significantly in T24, 5637 HLF and MCF-7 cells.…”

Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”